Fewer than 1,000 clinicians in the U.S. are trained to deliver CBT-I, leaving tens of millions of chronic insomnia patients with no access to the first-line treatment

Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as the first-line treatment for chronic insomnia by the American College of Physicians, the AASM, and the European Sleep Research Society -- yet there are fewer than 1,000 board-certified behavioral sleep medicine specialists in the United States to serve an estimated 30-40 million adults with chronic insomnia, creating waitlists of 6-12 months and forcing most patients toward sedative-hypnotic medications instead. Why it matters: patients who cannot access CBT-I are prescribed benzodiazepines, Z-drugs (zolpidem, eszopiclone), or trazodone as de facto treatment, so they face dependency risks, next-day cognitive impairment, and fall risk especially in the elderly, so the 2012 BMJ study showing zolpidem users had 3.6x higher mortality and 35% increased cancer incidence raises population-level safety concerns for the millions on long-term prescriptions, so healthcare spending on insomnia medications exceeds $2 billion annually in the U.S. while the evidence-based non-pharmacological alternative remains inaccessible, so the insomnia treatment gap becomes self-perpetuating because medical schools train psychiatrists and psychologists in medication management but not in the structured 6-8 session CBT-I protocol. The structural root cause is that CBT-I training requires specialized postdoctoral fellowship in behavioral sleep medicine, insurance reimbursement for the 6-8 session protocol is lower than a single medication management visit, and no scalable certification pathway exists to train the thousands of therapists, social workers, and nurse practitioners who could deliver it.